Compare Stocks: AKBA, ODTX, CRVS, and ABUS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$4.48 -4.1%	$4.85	$3.50 ▼ $5.45	$925.15M	0.76	8.13 million shs	8.26 million shs
AKBA Akebia Therapeutics	$0.88 -3.5%	$0.96	$0.81 ▼ $3.20	$252.30M	0.18	6.19 million shs	6.18 million shs
CRVS Corvus Pharmaceuticals	$10.56 -1.7%	$13.42	$6.39 ▼ $26.95	$903.46M	1.44	1.27 million shs	1.44 million shs
ODTX Odyssey Therapeutics	$18.13 -13.0%	$22.76	$15.10 ▼ $29.05	$1.00B	N/A	405,521 shs	340,662 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	+4.94%	-3.91%	-9.32%	-9.85%	+6.62%
AKBA Akebia Therapeutics	+5.26%	+1.95%	-6.59%	-32.56%	-67.83%
CRVS Corvus Pharmaceuticals	-1.47%	-9.52%	-25.36%	-31.29%	+49.37%
ODTX Odyssey Therapeutics	+0.53%	-2.93%	-27.54%	+30.99%	+2,083,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$4.48 -4.1%	$4.85	$3.50 ▼ $5.45	$925.15M	0.76	8.13 million shs	8.26 million shs
AKBA Akebia Therapeutics	$0.88 -3.5%	$0.96	$0.81 ▼ $3.20	$252.30M	0.18	6.19 million shs	6.18 million shs
CRVS Corvus Pharmaceuticals	$10.56 -1.7%	$13.42	$6.39 ▼ $26.95	$903.46M	1.44	1.27 million shs	1.44 million shs
ODTX Odyssey Therapeutics	$18.13 -13.0%	$22.76	$15.10 ▼ $29.05	$1.00B	N/A	405,521 shs	340,662 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	+4.94%	-3.91%	-9.32%	-9.85%	+6.62%
AKBA Akebia Therapeutics	+5.26%	+1.95%	-6.59%	-32.56%	-67.83%
CRVS Corvus Pharmaceuticals	-1.47%	-9.52%	-25.36%	-31.29%	+49.37%
ODTX Odyssey Therapeutics	+0.53%	-2.93%	-27.54%	+30.99%	+2,083,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	2.50	Moderate Buy	$5.00	11.61% Upside
AKBA Akebia Therapeutics	2.43	Hold	$3.90	343.94% Upside
CRVS Corvus Pharmaceuticals	2.88	Moderate Buy	$33.33	215.66% Upside
ODTX Odyssey Therapeutics	2.63	Moderate Buy	$35.75	97.19% Upside

Current Analyst Ratings Breakdown

Latest AKBA, ODTX, CRVS, and ABUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/16/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/16/2026	CRVS Corvus Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/15/2026	AKBA Akebia Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$4.00
9/8/2026	AKBA Akebia Therapeutics	Westpark Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$4.50
8/31/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	ODTX Odyssey Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$44.00
8/27/2026	ODTX Odyssey Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$44.00
8/26/2026	ABUS Arbutus Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/17/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/12/2026	ABUS Arbutus Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)

(Data available from 10/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$14.08M	63.04	N/A	N/A	$0.40 per share	11.20
AKBA Akebia Therapeutics	$236.20M	1.03	N/A	N/A	$0.12 per share	7.32
CRVS Corvus Pharmaceuticals	N/A	N/A	$0.12 per share	84.73	$0.73 per share	N/A
ODTX Odyssey Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$33.50M	$0.79	5.67	N/A	N/A	84.22%	90.98%	82.34%	11/16/2026 (Estimated)
AKBA Akebia Therapeutics	-$5.34M	-$0.11	N/A	N/A	N/A	-13.54%	-88.88%	-7.74%	11/9/2026 (Estimated)
CRVS Corvus Pharmaceuticals	-$15.28M	-$0.61	N/A	N/A	N/A	N/A	-36.15%	-33.62%	11/3/2026 (Estimated)
ODTX Odyssey Therapeutics	N/A	-$6.77	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest AKBA, ODTX, CRVS, and ABUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	CRVS Corvus Pharmaceuticals	-$0.1921	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	ABUS Arbutus Biopharma	-$0.02	-$0.03	-$0.01	-$0.03	$0.70 million	$1.01 million
8/6/2026	Q2 2026	CRVS Corvus Pharmaceuticals	-$0.1591	-$0.19	-$0.0309	-$0.19	N/A	N/A
8/5/2026	Q2 2026	AKBA Akebia Therapeutics	-$0.0420	-$0.02	+$0.0220	-$0.03	$48.85 million	$49.13 million
8/5/2026	Q2 2026	ODTX Odyssey Therapeutics	N/A	-$1.74	N/A	-$1.74	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ODTX Odyssey Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	N/A	81.42	81.42
AKBA Akebia Therapeutics	0.99	1.43	1.35
CRVS Corvus Pharmaceuticals	N/A	16.16	16.16
ODTX Odyssey Therapeutics	N/A	11.36	11.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
AKBA Akebia Therapeutics	33.92%
CRVS Corvus Pharmaceuticals	46.64%
ODTX Odyssey Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	19.90%
AKBA Akebia Therapeutics	4.30%
CRVS Corvus Pharmaceuticals	19.70%
ODTX Odyssey Therapeutics	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	19	198.11 million	158.68 million	Optionable
AKBA Akebia Therapeutics	194	277.11 million	265.19 million	Optionable
CRVS Corvus Pharmaceuticals	37	84.12 million	67.55 million	Optionable
ODTX Odyssey Therapeutics	100	48.06 million	N/A	N/A

AKBA, ODTX, CRVS, and ABUS Headlines

Recent News About These Companies

Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026

October 6 at 8:00 AM | globenewswire.com

Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Stock Rated "Moderate Buy" by Sell-Side Analysts

October 5 at 4:15 AM | americanbankingnews.com

Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Stock Has Consensus Target Price of $35.75 According to Brokerages

October 5 at 4:13 AM | marketbeat.com

State Street Corp Makes New $1.48 Million Investment in Odyssey Therapeutics, Inc. $ODTX

September 27, 2026 | marketbeat.com

Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum

September 16, 2026 | globenewswire.com

Odyssey Therapeutics (ODTX) Banks Two More Years As Trials Multiply

September 13, 2026 | insidermonkey.com

Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Receives Average Rating of "Moderate Buy" from Analysts

September 10, 2026 | marketbeat.com

Odyssey Therapeutics to Participate in Upcoming Investor Conferences

August 26, 2026 | globenewswire.com

Odyssey Therapeutics Inc.

August 18, 2026 | marketwatch.com

Odyssey Therapeutics: Q2 Earnings Snapshot

August 6, 2026 | chron.com

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

August 6, 2026 | prnewswire.com

Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 4, 2026 | globenewswire.com

Odyssey Therapeutics Stock Price History

July 16, 2026 | investing.com

Odyssey Therapeutics Inc ODTX

July 8, 2026 | morningstar.comM

Odyssey Therapeutics Inc ODTX

July 8, 2026 | morningstar.comM

Odyssey Therapeutics Inc Share Price (ODTX.US)

July 6, 2026 | lse.co.uk

Odyssey Therapeutics: Q1 Earnings Snapshot

June 18, 2026 | chron.com

Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

June 17, 2026 | globenewswire.com

Odyssey Therapeutics Inc

May 26, 2026 | money.usnews.com

A Boston biotech tried to go public last year but pulled back. Now it’s valued at nearly $1B

May 16, 2026 | finance.yahoo.com

Insider Buying: Odyssey Therapeutics (NASDAQ:ODTX) Major Shareholder Buys 1,388,889 Shares of Stock

May 14, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA, ODTX, CRVS, and ABUS Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$4.48 -0.19 (-4.07%)

Closing price 04:00 PM Eastern

Extended Trading

$4.54 +0.06 (+1.34%)

As of 07:30 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Akebia Therapeutics NASDAQ:AKBA

$0.88 -0.03 (-3.51%)

Closing price 04:00 PM Eastern

Extended Trading

$0.88 +0.00 (+0.51%)

As of 07:59 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Corvus Pharmaceuticals NASDAQ:CRVS

$10.56 -0.18 (-1.68%)

Closing price 04:00 PM Eastern

Extended Trading

$10.55 -0.01 (-0.09%)

As of 07:55 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Odyssey Therapeutics NASDAQ:ODTX

$18.13 -2.71 (-13.00%)

As of 04:00 PM Eastern

Odyssey Therapeutics Inc. is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc. is based in BOSTON.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AKBA, ODTX, CRVS, and ABUS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AKBA, ODTX, CRVS, and ABUS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AKBA, ODTX, CRVS, and ABUS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA, ODTX, CRVS, and ABUS Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

Akebia Therapeutics NASDAQ:AKBA

Corvus Pharmaceuticals NASDAQ:CRVS

Odyssey Therapeutics NASDAQ:ODTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AKBA, ODTX, CRVS, and ABUS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AKBA, ODTX, CRVS, and ABUS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AKBA, ODTX, CRVS, and ABUS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA, ODTX, CRVS, and ABUS Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

Akebia Therapeutics NASDAQ:AKBA

Corvus Pharmaceuticals NASDAQ:CRVS

Odyssey Therapeutics NASDAQ:ODTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools